Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
— Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement —
Covered in this story
Call it yourself
No calls on $IMMX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Immix Biopharma →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.